These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 37305703)

  • 1. Targeting PCSK9 reduces cancer cell stemness and enhances antitumor immunity in head and neck cancer.
    Yang QC; Wang S; Liu YT; Song A; Wu ZZ; Wan SC; Li HM; Sun ZJ
    iScience; 2023 Jun; 26(6):106916. PubMed ID: 37305703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of PCSK9 enhances the antitumor effect of PD-1 inhibitor in colorectal cancer by promoting the infiltration of CD8
    Wang R; Liu H; He P; An D; Guo X; Zhang X; Feng M
    Front Immunol; 2022; 13():947756. PubMed ID: 36003387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potentiating CD8
    Yuan J; Cai T; Zheng X; Ren Y; Qi J; Lu X; Chen H; Lin H; Chen Z; Liu M; He S; Chen Q; Feng S; Wu Y; Zhang Z; Ding Y; Yang W
    Protein Cell; 2021 Apr; 12(4):240-260. PubMed ID: 33606190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
    Urban D; Pöss J; Böhm M; Laufs U
    J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PCSK9 facilitates melanoma pathogenesis via a network regulating tumor immunity.
    Gu Y; Lin X; Dong Y; Wood G; Seidah NG; Werstuck G; Major P; Bonert M; Kapoor A; Tang D
    J Exp Clin Cancer Res; 2023 Jan; 42(1):2. PubMed ID: 36588164
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pseurotin A as a novel suppressor of hormone dependent breast cancer progression and recurrence by inhibiting PCSK9 secretion and interaction with LDL receptor.
    Abdelwahed KS; Siddique AB; Mohyeldin MM; Qusa MH; Goda AA; Singh SS; Ayoub NM; King JA; Jois SD; El Sayed KA
    Pharmacol Res; 2020 Aug; 158():104847. PubMed ID: 32438039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PCSK9 regulates the efficacy of immune checkpoint therapy in lung cancer.
    Gao X; Yi L; Jiang C; Li S; Wang X; Yang B; Li W; Che N; Wang J; Zhang H; Zhang S
    Front Immunol; 2023; 14():1142428. PubMed ID: 37025995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ascorbic acid enhances low-density lipoprotein receptor expression by suppressing proprotein convertase subtilisin/kexin 9 expression.
    Wang D; Yang X; Chen Y; Gong K; Yu M; Gao Y; Wu X; Hu H; Liao C; Han J; Duan Y
    J Biol Chem; 2020 Nov; 295(47):15870-15882. PubMed ID: 32913121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TIGIT/CD155 blockade enhances anti-PD-L1 therapy in head and neck squamous cell carcinoma by targeting myeloid-derived suppressor cells.
    Mao L; Xiao Y; Yang QC; Yang SC; Yang LL; Sun ZJ
    Oral Oncol; 2021 Oct; 121():105472. PubMed ID: 34333450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration.
    Zaid A; Roubtsova A; Essalmani R; Marcinkiewicz J; Chamberland A; Hamelin J; Tremblay M; Jacques H; Jin W; Davignon J; Seidah NG; Prat A
    Hepatology; 2008 Aug; 48(2):646-54. PubMed ID: 18666258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclase-associated protein 1 is a binding partner of proprotein convertase subtilisin/kexin type-9 and is required for the degradation of low-density lipoprotein receptors by proprotein convertase subtilisin/kexin type-9.
    Jang HD; Lee SE; Yang J; Lee HC; Shin D; Lee H; Lee J; Jin S; Kim S; Lee SJ; You J; Park HW; Nam KY; Lee SH; Park SW; Kim JS; Kim SY; Kwon YW; Kwak SH; Yang HM; Kim HS
    Eur Heart J; 2020 Jan; 41(2):239-252. PubMed ID: 31419281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tertiary Lymphoid Structure Raises Survival and Immunotherapy in HPV
    Li H; Zhu SW; Zhou JJ; Chen DR; Liu J; Wu ZZ; Wang WY; Zhang MJ; Sun ZJ
    J Dent Res; 2023 Jun; 102(6):678-688. PubMed ID: 36883630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proprotein convertase subtilisin/kexin type 9 (PCSK9): A potential multifaceted player in cancer.
    Bhattacharya A; Chowdhury A; Chaudhury K; Shukla PC
    Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188581. PubMed ID: 34144130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma Membrane Tetraspanin CD81 Complexes with Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Low Density Lipoprotein Receptor (LDLR), and Its Levels Are Reduced by PCSK9.
    Le QT; Blanchet M; Seidah NG; Labonté P
    J Biol Chem; 2015 Sep; 290(38):23385-400. PubMed ID: 26195630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sunitinib attenuates reactive MDSCs enhancing anti-tumor immunity in HNSCC.
    Liu J; Lin WP; Su W; Wu ZZ; Yang QC; Wang S; Sun TG; Huang CF; Wang XL; Sun ZJ
    Int Immunopharmacol; 2023 Jun; 119():110243. PubMed ID: 37137265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proprotein convertase subtilisin/kexin type 9 deficiency reduces melanoma metastasis in liver.
    Sun X; Essalmani R; Day R; Khatib AM; Seidah NG; Prat A
    Neoplasia; 2012 Dec; 14(12):1122-31. PubMed ID: 23308045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peroxisome Proliferator-activated receptor γ activation by ligands and dephosphorylation induces proprotein convertase subtilisin kexin type 9 and low density lipoprotein receptor expression.
    Duan Y; Chen Y; Hu W; Li X; Yang X; Zhou X; Yin Z; Kong D; Yao Z; Hajjar DP; Liu L; Liu Q; Han J
    J Biol Chem; 2012 Jul; 287(28):23667-77. PubMed ID: 22593575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proprotein Convertase Subtilisin/Kexin-Type 9 and Lipid Metabolism.
    Guo S; Xia XD; Gu HM; Zhang DW
    Adv Exp Med Biol; 2020; 1276():137-156. PubMed ID: 32705598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Single Domain Antibodies Are Potent Inhibitors of Low Density Lipoprotein Receptor Degradation.
    Weider E; Susan-Resiga D; Essalmani R; Hamelin J; Asselin MC; Nimesh S; Ashraf Y; Wycoff KL; Zhang J; Prat A; Seidah NG
    J Biol Chem; 2016 Aug; 291(32):16659-71. PubMed ID: 27284008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels.
    Ferri N; Tibolla G; Pirillo A; Cipollone F; Mezzetti A; Pacia S; Corsini A; Catapano AL
    Atherosclerosis; 2012 Feb; 220(2):381-6. PubMed ID: 22176652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.